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ORIGINAL RESEARCH
Sex Differences in Ischemic Stroke Outcomes 
in Patients With Pulmonary Hypertension
Tiberiu A. Pana , MRes; Dana K. Dawson , DPhil; Mohamed O. Mohamed , MRCP (UK); Fiona Murray , 
PhD; David L. Fischman , MD; Michael P. Savage , MD; Mamas A. Mamas , DPhil; Phyo K. Myint , MD
BACKGROUND: The association between systemic hypertension and cerebrovascular disease is well documented. However, 
the impact of pulmonary hypertension (PH) on acute ischemic stroke outcomes is unknown despite PH being recognized as 
a risk factor for acute ischemic stroke. We aimed to determine the association between PH and adverse in- hospital outcomes 
after acute ischemic stroke, as well as whether there are sex differences in this association.
METHODS AND RESULTS: Acute ischemic stroke admissions from the US National Inpatient Sample between October 2015 and 
December 2017 were included. The relationship between PH and outcomes (mortality, prolonged hospitalization >4 days, 
and routine home discharge) was analyzed using logistic regressions adjusting for demographics, comorbidities, and re-
vascularization therapies. Interaction terms between PH and sex and age groups were also included. A total of 221 249 
records representative of 1 106 045 admissions were included; 2.9% of patients had co- morbid PH, and 35.34% of those 
were male. PH was not associated with in- hospital mortality (odds ratio [OR], 0.96; 95% CI, 0.86– 1.09) but was associated 
with increased odds of prolonged hospitalization (OR, 1.15; 95% CI, 1.09– 1.22) and decreased odds of routine discharge 
(OR, 0.87; 95% CI, 0.81– 0.94) for both sexes. Older patients with PH were significantly less likely to be discharged routinely 
(P=0.028) than their younger counterparts. Compared with female patients with PH, men were 31% more likely to die in 
hospital (P=0.024).
CONCLUSIONS: PH was not significantly associated with in- hospital mortality but was associated with prolonged hospitalization 
and adverse discharge status. Male patients with PH were more likely to die in hospital than female patients.
Key Words: hospitalization ■ outcomes ■ pulmonary hypertension ■ stroke
Pulmonary hypertension (PH) is a disorder affecting the pulmonary vascular bed and is characterized by increased mean pulmonary arterial pressure 
(>20 mm Hg), as confirmed by right heart catheteriza-
tion.1 PH is a heterogenous clinical entity and may be 
classified into 5 categories based on pathophysiology, 
clinical features, hemodynamic features, and manage-
ment.1 The epidemiology of PH is similarly heteroge-
nous and varies among different clinical PH classes.2 
While pulmonary arterial hypertension (PAH – group 
1 PH) is a relatively uncommon disease, with an es-
timated prevalence between 5 and 52 per million,2,3 
PH secondary to pulmonary disease or left heart 
disease (groups 2 and 3) is much more common.4– 7 
Furthermore, there are important sex differences in the 
epidemiology of PH: While female patients are more 
likely to develop the disease, male patients are more 
likely to have poorer outcomes.8,9
PH is associated with incident acute ischemic 
stroke (AIS),10 with comorbidities such as atrial fibril-
lation (AF) and cerebral venous congestion acting as 
likely mediators.10 In addition, endothelial dysfunc-
tion and decreased nitric oxide synthesis may also 
act as contributing pathophysiological processes, 
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given their involvement in the pathogenesis of both 
stroke11,12 and PH.13 This suggests an increased 
stroke burden among patients with PH than in the 
general population. Furthermore, given that PH 
may cause right ventricular failure14 and decreased 
cardiac functional reserve15 and may thus render 
patients more susceptible to the hemodynamic in-
stability and cardiac complications associated with 
acute stroke,16,17 it may be associated with worse 
AIS outcomes. Nevertheless, there are no studies 
evaluating the impact of PH on AIS outcomes. This 
relationship is important, given that patients with 
PH not only have a higher stroke incidence than 
the general population but may also be more vul-
nerable to acute stroke complications. The identi-
fication of such relationships would not only alert 
clinicians treating patients with AIS with coexisting 
PH but also lead to further research efforts aiming 
to reduce the burden of stroke and stroke- related 
mortality among patients with PH. Furthermore, it 
also remains unknown whether any sex differences 
exist in the acute ischemic stroke outcomes of pa-
tients with PH.
In this study, we aimed to determine the association 
between PH and AIS in- hospital outcomes (mortality, 
length of hospitalization and routine home discharge) 
as well as to determine whether any sex differences 
exist. Furthermore, given that the etiology and progno-
sis of pulmonary hypertension also varies with age,8,18 
we also aimed to determine whether any differences in 
the association between PH and AIS outcomes exist 
between different age groups.
METHODS
This study was conducted in accordance with the 
principles of the Declaration of Helsinki (1975) and later 
amendments. The data that support the findings of 
this study are available from the corresponding author 
upon reasonable request.
Data Source and Inclusion Criteria
The National Inpatient Sample (NIS) is a large pub-
licly available database containing >7 million annual 
hospital admission records in the United States. The 
NIS contains admission records representing a 20% 
stratified sample of all community hospital admis-
sions in the United States in a given time frame. Using 
the provided sampling weights, the NIS data can be 
used to provide national estimates for the sampling 
population, representative of ~95% of the US popula-
tion.19,20 Before undertaking this project, all authors 
completed the online Healthcare Cost and Utilization 
Project Data Use Agreement Training Tool. All au-
thors also read and signed the Data Use Agreement 
for Nationwide Databases. As the NIS is a publicly 
available database with no patient identifiable infor-
mation, no ethical approval was needed. Using data 
files containing annual admissions between 2015 and 
2017, all records with a primary diagnosis of ischemic 
stroke (International Classification of Diseases, Tenth 
Revision [ICD- 10] codes I63.0- I63.9) were extracted. 
Only cases admitted between October 2015 and 
December 2017 were included because of a change 
CLINICAL PERSPECTIVE
What Is New?
• The association and underlying sex differences 
between comorbid pulmonary hypertension 
(PH) and acute ischemic stroke (AIS) in- hospital 
outcomes are described for the first time in this 
study, using a sample representative of 1.1 mil-
lion AIS admissions between 2015 and 2017 
from the US National Inpatient Sample.
• There was no association between PH and 
mortality, but PH was associated with a 15% 
increase in the odds of prolonged hospitaliza-
tion and a 31% decrease in the odds of routine 
home discharge.
• Male patients with PH were at 31% increased 
odds of dying in the hospital after AIS com-
pared with their female counterparts.
What Are the Clinical Implications?
• Clinicians should be aware of both the excess 
odds of adverse AIS in- hospital outcomes in 
patients with PH and the sex differences in mor-
tality recorded in this population.
• Patients with AIS and PH, especially men, may 
benefit from therapeutic strategies personalized 
to their comorbidity profile, which may mitigate 
the PH- associated excess odds of adverse out-
comes, such as early cardiovascular and chest 
physician assessment in the early stages after 
AIS.
• The associations between PH and AIS may 
be at least partly mediated by atrial fibrillation, 
and thus systematic atrial fibrillation screening 
may be advocated, since appropriate atrial fi-
brillation management may improve AIS- related 
outcomes.
Nonstandard Abbreviations and Acronyms
AIS acute ischemic stroke
NIS National Inpatient Sample
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in comorbidity coding (International Classification of 
Diseases, Ninth Revision [ICD- 9] to ICD- 10) occurring 
after September 2015.20
Figure 1 details the study population. Of 230 177 
records extracted from the NIS with a primary diagno-
sis of ischemic stroke admitted between October 2015 
and December 2017, a total of 8708 elective admission 
records as well as 220 records with missing data were 
excluded, yielding a total of 221 249 included records. 
Elective admissions were excluded to ensure that only 
admissions that were triggered by the acute stroke 
event were included. After the application of sampling 
weights and the exclusion of strata with single sam-
pling units, the included records were used to provide 
estimates for the population from which they were 
sampled: 1 106 045 patients admitted with a primary 
diagnosis of AIS.
Statistical Analysis
All analyses were performed using Stata 15.1SE 
(StataCorp, College Station, TX). A 5% threshold 
of statistical significance was used for all analyses 
(P<0.05). All analyses were performed according to 
Healthcare Cost and Utilization Project guidelines,21 
using the provided discharge weights as probability 
weights and survey data analysis techniques stratify-
ing by NIS stratum and year of admission22 to account 
for patient clustering within hospitals and produce US- 
wide estimates.23
Outcomes
The following outcomes were analyzed: (1) in- hospital 
mortality, (2) prolonged hospital stay in excess of 4 
days, and (3) routine discharge from the hospital. 
Vital status upon hospital discharge (dead/alive) and 
the length of stay (LOS) in the hospital are provided 
as standard variables in the NIS.24,25 Prolonged hos-
pitalization was defined as LOS >4 days, according 
to expert clinical opinion and previous studies as-
sessing ischemic stroke outcomes among patients 
admitted to the hospital in the United States.26 A 
dichotomous variable indicating patients hospi-
talized for >4  days was subsequently used as an 
outcome for LOS analyses. Discharge status was 
coded using the provided discharge destination.27 
All records of patients who were discharged against 
medical advice and those discharged to an unknown 
destination were excluded from the analyses before 
weighting (n=2187; 0.99%), allowing estimates for 
this particular outcome to be provided for 1 095 110 
(99.01%) of patients with AIS. Discharge destination 
was then dichotomized into routine discharges and 
other discharges (“home health care,” “short- term 
hospital,” “other facilities including intermediate care 
and skilled nursing home,” and “died in hospital”). 
The “other discharges” category was subsequently 
used as a reference category in all analyses evaluat-
ing discharge destination.
Exposure and Confounders
Comorbid PH was the exposure of interest. All mod-
els were adjusted for the following confounders: age, 
sex, ethnicity, Elixhauser comorbidities (congestive 
heart failure, valvular disease, peripheral vascular 
disease, paralysis, other neurological disorders, 
chronic pulmonary disease, diabetes mellitus, hypo-
thyroidism, renal failure, liver disease, peptic ulcer 
disease, acquired immune deficiency syndrome, 
lymphoma, metastatic cancer, solid tumour with-
out metastasis, rheumatoid arthritis, coagulopathy, 
obesity, weight loss, fluid and electrolyte disorders, 
anemia, alcohol abuse, drug abuse, psychosis, de-
pression, and hypertension), other comorbidities 
(dyslipidemia, smoking, coronary heart disease, all- 
cause bleeding, deep venous thrombosis/pulmo-
nary embolism, pericarditis, infectious endocarditis, 
atrial fibrillation, pneumonia [including aspiration], 
chronic lung disease, shock, family history of cere-
brovascular disease, family history of heart disease, 
previous cerebrovascular disease), hospital location 
and teaching status, and revascularization therapy 
(thrombolysis, thrombectomy). Adjusting covariates 
were selected on the basis of clinical judgment and 
previous literature assessing the relationship be-
tween cardiovascular comorbidities and acute AIS 
outcomes.28– 32
Diagnoses of PH and comorbid conditions were 
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diagnoses assigned before or during the index acute 
ischemic stroke hospitalization. Elixhauser comor-
bidities were determined using the Healthcare Cost 
and Utilization Project Elixhauser comorbidity soft-
ware.33,34 To gain insight into the distribution of likely 
etiologies of PH in the included samples, combina-
tions of ICD- 10 codes were employed to approximate 
the World Health Organization classification of PH2 
(Table S2).
Descriptive Statistics
Patient characteristics were compared between pa-
tients with and without PH as well as between male 
and female patients with PH. Independent- sample t- 
test and Pearson’s chi- squared test were employed 
to compare patient characteristics for continuous and 
categorical variables, respectively.
Association Between Pulmonary 
Hypertension and In- Hospital Outcomes
Logistic regressions were employed to model the re-
lationship between prevalent PH and all in- hospital 
outcomes and were adjusted for the confound-
ers listed above. Interaction terms with sex and age 
were assessed to determine sex or age differences. 
Multivariable logistic regressions modeling the relation-
ship between PH and in- hospital post- AIS outcomes 
were also performed separately for the different sex 
and age strata (≤40 years, 40– 50 years, 50– 60 years, 
60– 70 years, 70– 80 years, > 80 years).
Further stratified analyses were performed to de-
termine the potential interactions between the relation-
ship between PH and AIS outcomes and potential/
likely prestroke treatment with lipid- lowering and an-
ticoagulant agents. Despite the fact that the NIS does 
not record patient medication data, preexisting dys-
lipidemia/atherosclerotic vascular disease and AF 
were used as surrogates for likely pretreatment with 
lipid- lowering and anticoagulant agents, respectively, 
assuming compliance with contemporary primary and 
secondary cardiovascular prevention guidelines.35,36 
Atherosclerotic vascular disease was defined as a 
composite of coronary heart disease, peripheral vas-
cular disease, and previous stroke/transient ischemic 
attack.
Sensitivity LOS Analyses
Sensitivity analyses were also undertaken for this 
outcome only including patients surviving to hos-
pital discharge to ascertain potential biases intro-
duced in the main analyses by censoring due to 
deaths occurring before hospital discharge. The 




Table 1 details the patient characteristics on admis-
sion, stratified by the presence or absence of PH. In a 
total sample of 1 106 045 included patients, the me-
dian (interquartile range) age was 72 (61– 82) years, 
and there were 557  595 (50.41%) women. The re-
corded median (interquartile range) LOS was 3 (2– 6) 
days. There were 31  830 (2.88%) patients with PH. 
Compared with patients without PH, those with PH 
were significantly older (median age, 71 and 80 years, 
respectively), and there was a higher proportion of 
women (49.99% versus 64.66%, respectively). Patients 
with PH also spent a significantly longer time in the 
hospital and were significantly more likely to suffer 
from cardiovascular, pulmonary, and other comorbidi-
ties compared with those without PH. Compared with 
patients without PH, those with PH were more likely to 
have coexisting AF (24.58% versus 56.83%, respec-
tively). A total of 103 600 (9.37%) and 34 420 (3.11%) 
patients underwent intravenous thrombolysis and en-
dovascular thrombectomy, respectively. Patients with 
PH were also more likely to receive revascularization 
therapies compared with those without: intravenous 
thrombolysis (11.26% versus 9.31%) and endovascular 
thrombectomy (5.17% versus 3.05%). Compared with 
patients without PH, those with PH had a significantly 
higher proportion of in- hospital mortality (3.86% ver-
sus 6.52%), prolonged hospitalization in excess of 4 
days (33.99% versus 48.71%), and a significantly lower 
proportion of routine home discharges (37.54% versus 
21.83%).
Figure 2 details the distribution of the likely underly-
ing etiology of pulmonary hypertension in the included 
sample. Of 31  830 patients with AIS with coexisting 
PH, there were 155 (0.49%) patients with PAH, 17 210 
(54.07%) patients with PH and coexisting left heart 
disease, 5370 (16.87%) patients with PH and coexist-
ing left heart disease and chronic lung disease, 1825 
(5.73%) patients with PH and chronic lung disease, 
550 (1.73%) patients with chronic thromboembolic PH, 
and 6720 (21.11%) patients with PH with likely other 
etiologies.
Table 2 details the characteristics on admission of 
patients with PH, stratified by sex. Of a total of 31 830 
patients with PH with stroke, 11  250 (35.34%) were 
men. Compared with women, men were significantly 
younger (median age (interquartile range), 76 (66– 85) 
years and 82 (72– 88) years for men and women, re-
spectively; P <0.001). Men were more likely to have 
comorbid congestive heart failure, peripheral vascu-
lar disease, diabetes mellitus, renal failure, and liver 
disease. Conversely, women were more likely to have 
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N 1 106 045 1 074 215 31 830
Age, y, median (IQR) 72.00 
(61.00– 82.00)
71.00 (60.00– 82.00) 80.00 (69.00– 87.00) <0.001†
Length of stay, d, median (IQR) 3.00 (2.00– 6.00) 3.00 (2.00– 6.00) 4.00 (3.00– 7.00) <0.001†
Sex
Female, n (%) 557 595 (50.41) 537 015 (49.99) 20 580 (64.66) <0.001†
Race/Ethnicity, n (%)
White 735 330 (66.48) 713 675 (66.44) 21 655 (68.03) <0.001†
Black 183 090 (16.55) 177 555 (16.53) 5535 (17.39)
Hispanic 84 950 (7.68) 83 225 (7.75) 1725 (5.42)
Asian or Pacific Islander 31 635 (2.86) 30 825 (2.87) 810 (2.54)
Native American 4700 (0.42) 4590 (0.43) 110 (0.35)
Other 27 460 (2.48) 26 805 (2.50) 655 (2.06)
Year of admission, n (%)
2015 112 000 (10.13) 108 485 (10.10) 3515 (11.04) <0.001†
2016 488 005 (44.12) 472 110 (43.95) 15 895 (49.94)
2017 506 040 (45.75) 493 620 (45.95) 12 420 (39.02)
Elixhauser comorbidities, n (%)
Congestive heart failure 172 170 (15.57) 157 020 (14.62) 15 150 (47.60) <0.001†
Valvular disease 110 540 (9.99) 97 195 (9.05) 13 345 (41.93) <0.001†
Pulmonary circulation disease 8460 (0.76) 6525 (0.61) 1935 (6.08) <0.001†
Peripheral vascular disease 112 065 (10.13) 107 395 (10.00) 4670 (14.67) <0.001†
Paralysis 112 895 (10.21) 108 455 (10.10) 4440 (13.95) <0.001†
Other neurological disorders 6620 (0.60) 6250 (0.58) 370 (1.16) <0.001†
Chronic pulmonary disease 174 180 (15.75) 165 835 (15.44) 8345 (26.22) <0.001†
Diabetes mellitus (without chronic 
complications)
210 220 (19.01) 204 970 (19.08) 5250 (16.49) <0.001†
Diabetes mellitus (with chronic complications) 214 400 (19.38) 207 960 (19.36) 6440 (20.23) 0.091
Hypothyroidism 159 160 (14.39) 153 230 (14.26) 5930 (18.63) <0.001†
Renal failure 181 950 (16.45) 172 590 (16.07) 9360 (29.41) <0.001†
Liver disease 18 310 (1.66) 17 545 (1.63) 765 (2.40) <0.001†
Peptic ulcer disease 7695 (0.70) 7370 (0.69) 325 (1.02) 0.001†
AIDS 2395 (0.22) 2335 (0.22) 60 (0.19) 0.647
Lymphoma 5315 (0.48) 5095 (0.47) 220 (0.69) 0.013†
Metastatic cancer 17 955 (1.62) 17 405 (1.62) 550 (1.73) 0.498
Solid tumor without metastasis 19 670 (1.78) 18 965 (1.77) 705 (2.21) 0.006†
Rheumatoid arthritis/collagen vascular disease 30 150 (2.73) 28 755 (2.68) 1395 (4.38) <0.001†
Coagulopathy 41 405 (3.74) 39 300 (3.66) 2105 (6.61) <0.001†
Obesity 145 465 (13.15) 140 800 (13.11) 4665 (14.66) <0.001†
Weight loss 44 030 (3.98) 41 720 (3.88) 2310 (7.26) <0.001†
Fluid and electrolyte disorders 246 680 (22.30) 236 775 (22.04) 9905 (31.12) <0.001†
Anemia (chronic blood loss) 4025 (0.36) 3775 (0.35) 250 (0.79) <0.001†
Anemia (deficiency) 133 005 (12.03) 125 880 (11.72) 7125 (22.38) <0.001†
Alcohol abuse 49 375 (4.46) 48 415 (4.51) 960 (3.02) <0.001†
Drug abuse 28 985 (2.62) 28 385 (2.64) 600 (1.89) <0.001†
Psychoses 26 255 (2.37) 25 745 (2.40) 510 (1.60) <0.001†
Depression 124 635 (11.27) 120 880 (11.25) 3755 (11.80) 0.179
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Other comorbidities, n (%)
Atrial fibrillation 282 175 (25.51) 264 085 (24.58) 18 090 (56.83) <0.001†
Sepsis 16 400 (1.48) 15 730 (1.46) 670 (2.10) <0.001†
Dyslipidemia 640 010 (57.86) 621 995 (57.90) 18 015 (56.60) 0.038†
Dementia 131 650 (11.90) 126 515 (11.78) 5135 (16.13) <0.001†
Smoking 203 440 (18.39) 200 240 (18.64) 3200 (10.05) <0.001†
Parkinson disease 15 795 (1.43) 15 340 (1.43) 455 (1.43) 0.992
Transient ischemic attack 8070 (0.73) 7875 (0.73) 195 (0.61) 0.262
Rheumatic heart disease 32 355 (2.93) 25 415 (2.37) 6940 (21.80) <0.001†
Coronary heart disease 314 870 (28.47) 301 100 (28.03) 13 770 (43.26) <0.001†
All- cause bleeding 79 995 (7.23) 76 540 (7.13) 3455 (10.85) <0.001†
Pulmonary embolism 7000 (0.63) 6435 (0.60) 565 (1.78) <0.001†
Congenital heart disease 33 495 (3.03) 32 390 (3.02) 1105 (3.47) 0.040†
Pericarditis 105 (0.01) 90 (0.01) 15 (0.05) 0.002†
Infectious endocarditis 2310 (0.21) 2175 (0.20) 135 (0.42) <0.001†
Deep venous thrombosis 14 845 (1.34) 14 025 (1.31) 820 (2.58) <0.001†
Pneumonia 29 905 (2.70) 28 205 (2.63) 1700 (5.34) <0.001†
Chronic lung disease 136 505 (12.34) 129 120 (12.02) 7385 (23.20) <0.001†
Chronic obstructive pulmonary disease 126 505 (11.44) 119 775 (11.15) 6730 (21.14) <0.001†
Shock 5070 (0.46) 4695 (0.44) 375 (1.18) <0.001†
Family history of cerebrovascular disease 42 725 (3.86) 41 760 (3.89) 965 (3.03) 0.001†
Family history of heart disease 640 00 (5.79) 62 265 (5.80) 1735 (5.45) 0.249
Previous cerebrovascular disease 172 600 (15.61) 167 715 (15.61) 4885 (15.35) 0.569
Outcomes, n (%)
In- hospital mortality 43 545 (3.94) 41 470 (3.86) 2075 (6.52) <0.001†
Length of stay >4 days 380 605 (34.41) 365 100 (33.99) 15 505 (48.71) <0.001†
Routine discharge 394 105 (37.10) 387 610 (37.54) 6495 (21.83) <0.001†
Other characteristics, n (%)
Hospital bed size
Small 174 745 (15.80) 169 930 (15.82) 4815 (15.13) 0.236
Medium 324 895 (29.37) 315 720 (29.39) 9175 (28.82)
Large 606 405 (54.83) 588 565 (54.79) 17 840 (56.05)
Location/teaching status of hospital
Rural 82 535 (7.46) 80 480 (7.49) 2055 (6.46) 0.032†
Urban nonteaching 266 440 (24.09) 258 660 (24.08) 7780 (24.44)
Urban teaching 757 070 (68.45) 735 075 (68.43) 21 995 (69.10)
Region of hospital
Northeast 198 830 (17.98) 193 045 (17.97) 5785 (18.17) <0.001†
Midwest 238 555 (21.57) 231 020 (21.51) 7535 (23.67)
South 461 280 (41.71) 449 410 (41.84) 11 870 (37.29)
West 207 380 (18.75) 200 740 (18.69) 6640 (20.86)
All Patient Refined Diagnosis Related Group: Severity of illness subclass
Minor loss of function 89 400 (8.08) 89 400 (8.32) <11* …
Moderate loss of function 541 350 (48.94) 533 440 (49.66) 7910 (24.85)
Major loss of function 365 580 (33.05) 347 890 (32.39) 17 690 (55.58)
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rheumatoid arthritis, and depression. There were no 
statistically significant sex differences in rates of intra-
venous thrombolysis and endovascular thrombectomy 
among patients with PH. There were also no statisti-
cally significant sex differences in the proportion of pa-
tients with PH dying in the hospital (7.20% and 6.15% 
for men and women, respectively) or undergoing pro-
longed hospitalization (48.76% and 48.69% for men 
and women, respectively). Nevertheless, significantly 
fewer female patients with PH were discharged rou-
tinely than male patients with PH (17.66% and 25.76%, 
respectively).
Tables S3 and S4 detail the patient characteristics 
on admission, stratified by age group as well as PH. 
Regardless of age group, patients with coexisting PH 
had significantly longer LOS than those without PH. 
Nevertheless, the relative difference between patients 
with and without PH decreased with advancing age, as 
the LOS of patients with PH decreased while that of pa-
tients without PH increased. Patients with PH >50 years 
old, but not those <50 years old, were significantly more 
likely to be women. The female- to- male difference 
among patients with PH increased with increasing age.
Association Between PH and In- Hospital 
Outcomes
Figure 3 and Table 3 detail the results of the logistic re-
gressions assessing the association between PH and 
post- AIS in- hospital outcomes. Figure 4 provides a 
visual summary of the main study findings. The overall 
regression results of the association between PH and 
outcomes were derived from models not containing 
any interaction terms.
There was no association between PH and in- hospital 
mortality (odds ratio [OR], 1.02; 95% CI, 0.91– 1.15). 
However, there was a significant sex interaction (OR, 0.76; 
95% CI, 0.60– 0.97; P=0.024). PH was associated with 
a nonsignificant 15% increase in the odds of in- hospital 
mortality among men (OR, 1.15; 95% CI, 0.95– 1.38) but 
not among women (OR, 0.88; 95% CI, 0.75– 1.02). There 
were no significant interactions with age.
PH was significantly associated with prolonged 
LOS >4 days (OR, 1.15; 95% CI, 1.09– 1.22). There 
were no significant interactions with sex or age for this 
outcome.
PH was also significantly associated with decreased 
odds of routine home discharge (OR, 0.85; 95% CI, 
0.79– 0.91). There were no significant interactions with 
sex for this outcome. Nevertheless, there was a sig-
nificant age interaction (P=0.028). Older patients were 
less likely to be discharged home, therefore requiring 
further rehabilitation or institutionalization after dis-
charge: (OR for interaction term between PH and 10- 
year increase in age, 0.94; 95% CI, 0.89– 0.993).
Table 3 also details the interaction terms with pre-






Disposition of the patient at discharge, n (%)
Routine discharge 394 105 (35.63) 387 610 (36.08) 6495 (20.41) …
Transfer to short- term hospital 31 995 (2.89) 31 305 (2.91) 690 (2.17)
Transfer to other facility: Includes skilled 
nursing facility, intermediate care facility, 
another type of facility
468 640 (42.37) 451 480 (42.03) 17 160 (53.91)
Home health care 156 825 (14.18) 151 585 (14.11) 5240 (16.46)
Against medical advice 10 685 (0.97) 10 515 (0.98) 170 (0.53)
Died 43 545 (3.94) 41 470 (3.86) 2075 (6.52)
Discharged alive, destination unknown 250 (0.02) 250 (0.02) <11*
IQR indicates interquartile range.
*Cell sizes ≤10 were not reported to avoid patient re- identification, according to the Healthcare Cost and Utilization Project guidelines21.
†Statistically significant differences (P<0.05).
Table 1. Continued
Figure 2. Bar chart detailing the distribution of the likely 
underlying etiologies of pulmonary hypertension in the 
included patient sample (total N with PH = 31 830).
CLD indicates chronic lung disease; CTEPH, chronic 
thromboembolic pulmonary hypertension; LHD, left heart 
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Table 2. Patient Characteristics on Admission for Patients With Comorbid Pulmonary Hypertension, Stratified by Sex
All (Pulmonary Hypertension) Male Female P Value
N 31 830 11 250 20 580
Age, y, median (IQR) 80.00 (69.00– 87.00) 76.00 
(66.00– 85.00)
82.00 (72.00– 88.00) <0.001†
Length of stay, d, median (IQR) 4.00 (3.00– 7.00) 4.00 (3.00– 8.00) 4.00 (3.00– 7.00) 0.547
Race/Ethnicity, n (%)
White 21 655 (68.03) 7645 (67.96) 14 010 (68.08) 0.640
Black 5535 (17.39) 1860 (16.53) 3675 (17.86)
Hispanic 1725 (5.42) 660 (5.87) 1065 (5.17)
Asian or Pacific Islander 810 (2.54) 305 (2.71) 505 (2.45)
Native American 110 (0.35) 45 (0.40) 65 (0.32)
Other 655 (2.06) 225 (2.00) 430 (2.09)
Missing 1340 (4.21) 510 (4.53) 830 (4.03)
Year of admission, n (%)
2015 3515 (11.04) 1315 (11.69) 2200 (10.69) 0.016†
2016 15 895 (49.94) 5345 (47.51) 10 550 (51.26)
2017 12 420 (39.02) 4590 (40.80) 7830 (38.05)
Elixhauser comorbidities, n (%)
Congestive heart failure 15 150 (47.60) 5670 (50.40) 9480 (46.06) 0.001†
Valvular disease 13 345 (41.93) 4585 (40.76) 8760 (42.57) 0.159
Pulmonary circulation disease 1935 (6.08) 695 (6.18) 1240 (6.03) 0.816
Peripheral vascular disease 4670 (14.67) 1870 (16.62) 2800 (13.61) 0.001†
Paralysis 4440 (13.95) 1505 (13.38) 2935 (14.26) 0.333
Other neurological disorders 370 (1.16) 135 (1.20) 235 (1.14) 0.836
Chronic pulmonary disease 8345 (26.22) 2870 (25.51) 5475 (26.60) 0.344
Diabetes mellitus (without chronic 
complications)
5250 (16.49) 1830 (16.27) 3420 (16.62) 0.721
Diabetes mellitus (with chronic 
complications)
6440 (20.23) 2485 (22.09) 3955 (19.22) 0.007†
Hypothyroidism 5930 (18.63) 1105 (9.82) 4825 (23.45) <0.001†
Renal failure 9360 (29.41) 3595 (31.96) 5765 (28.01) 0.001†
Liver disease 765 (2.40) 365 (3.24) 400 (1.94) 0.001†
Peptic ulcer disease 325 (1.02) 125 (1.11) 200 (0.97) 0.598
Lymphoma 220 (0.69) 100 (0.89) 120 (0.58) 0.160
Metastatic cancer 550 (1.73) 185 (1.64) 365 (1.77) 0.709
Solid tumor without metastasis 705 (2.21) 300 (2.67) 405 (1.97) 0.072
Rheumatoid arthritis/collagen vascular 
disease
1395 (4.38) 255 (2.27) 1140 (5.54) <0.001†
Coagulopathy 2105 (6.61) 1020 (9.07) 1085 (5.27) <0.001†
Obesity 4665 (14.66) 1645 (14.62) 3020 (14.67) 0.953
Weight loss 2310 (7.26) 735 (6.53) 1575 (7.65) 0.103
Fluid and electrolyte disorders 9905 (31.12) 3340 (29.69) 6565 (31.90) 0.069
Anemia (chronic blood loss) 250 (0.79) 80 (0.71) 170 (0.83) 0.620
Anemia (deficiency) 7125 (22.38) 2475 (22.00) 4650 (22.59) 0.593
Alcohol abuse 960 (3.02) 655 (5.82) 305 (1.48) <0.001†
Drug abuse 600 (1.89) 325 (2.89) 275 (1.34) <0.001†
Psychoses 510 (1.60) 175 (1.56) 335 (1.63) 0.827
Depression 3755 (11.80) 1070 (9.51) 2685 (13.05) <0.001†





 http://ahajournals.org by on A
pril 9, 2021
J Am Heart Assoc. 2021;10:e019341. DOI: 10.1161/JAHA.120.019341 9
Pana et al Pulmonary Hypertension Sex Differences in Stroke
All (Pulmonary Hypertension) Male Female P Value
Other comorbidities, n (%)
Atrial fibrillation 18 090 (56.83) 6180 (54.93) 11 910 (57.87) 0.022†
Sepsis 670 (2.10) 265 (2.36) 405 (1.97) 0.287
Dyslipidemia 18 015 (56.60) 6305 (56.04) 11 710 (56.90) 0.516
Dementia 5135 (16.13) 1320 (11.73) 3815 (18.54) <0.001†
Smoking 3200 (10.05) 1565 (13.91) 1635 (7.94) <0.001†
Parkinson disease 455 (1.43) 220 (1.96) 235 (1.14) 0.010†
Transient ischemic attack 195 (0.61) 75 (0.67) 120 (0.58) 0.684
Rheumatic heart disease 6940 (21.80) 2295 (20.40) 4645 (22.57) 0.046†
Coronary heart disease 13 770 (43.26) 5820 (51.73) 7950 (38.63) <0.001†
All- cause bleeding 3455 (10.85) 1295 (11.51) 2160 (10.50) 0.192
Pulmonary embolism 565 (1.78) 180 (1.60) 385 (1.87) 0.431
Congenital heart disease 1105 (3.47) 360 (3.20) 745 (3.62) 0.368
Pericarditis 15 (0.05) <11* <11* 0.942
Infectious endocarditis 135 (0.42) 60 (0.53) 75 (0.36) 0.321
Deep venous thrombosis 820 (2.58) 335 (2.98) 485 (2.36) 0.142
Pneumonia 1700 (5.34) 745 (6.62) 955 (4.64) 0.001†
Chronic lung disease 7385 (23.20) 2650 (23.56) 4735 (23.01) 0.627
Chronic obstructive pulmonary disease 6730 (21.14) 2400 (21.33) 4330 (21.04) 0.786
Shock 375 (1.18) 215 (1.91) 160 (0.78) <0.001†
Family history of cerebrovascular disease 965 (3.03) 340 (3.02) 625 (3.04) 0.974
Family history of heart disease 1735 (5.45) 600 (5.33) 1135 (5.52) 0.755
Previous cerebrovascular disease 4885 (15.35) 1580 (14.04) 3305 (16.06) 0.030†
Outcomes, n (%)
In- hospital mortality 2075 (6.52) 810 (7.20) 1265 (6.15) 0.097
Length of stay >4 days 15 505 (48.71) 5485 (48.76) 10 020 (48.69) 0.958
Routine discharge 6495 (20.51) 2875 (25.76) 3620 (17.66) <0.001†
Other characteristics, n (%)
Hospital bed size, n (%)
Small 4815 (15.13) 1590 (14.13) 3225 (15.67) 0.058
Medium 9175 (28.82) 3135 (27.87) 6040 (29.35)
Large 17 840 (56.05) 6525 (58.00) 11 315 (54.98)
Location/teaching status of hospital
Rural 2055 (6.46) 775 (6.89) 1280 (6.22) 0.578
Urban nonteaching 7780 (24.44) 2730 (24.27) 5050 (24.54)
Urban teaching 21 995 (69.10) 7745 (68.84) 14 250 (69.24)
Region of hospital
Northeast 5785 (18.17) 1915 (17.02) 3870 (18.80) 0.002†
Midwest 7535 (23.67) 2525 (22.44) 5010 (24.34)
South 11 870 (37.29) 4195 (37.29) 7675 (37.29)
West 6640 (20.86) 2615 (23.24) 4025 (19.56)
All Patient Refined Diagnosis Related Group: severity of illness subclass
Minor loss of function <11* <11* <11* 0.018†
Moderate loss of function 7910 (24.85) 2675 (23.78) 5235 (25.44)
Major loss of function 17 690 (55.58) 6170 (54.84) 11 520 (55.98)
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and AF. Upon full multivariable adjustment, preexisting 
dyslipidemia or atherosclerotic cardiovascular disease, 
as markers of likely prestroke lipid- lowering treatment, 
were not associated with changes in the association 
between PH and any outcomes. Nevertheless, preex-
isting AF, as a marker of likely prestroke anticoagulant 
treatment, was associated with a decrease in the as-
sociation between PH and in- hospital mortality (OR, 
0.77; 95% CI, 0.61– 0.98) as well as prolonged hospi-
talization (OR, 0.88; 95% CI, 0.79– 0.99).
Sensitivity LOS Analyses
Figure S1 details the results of the sensitivity analyses 
including only patients surviving to hospital discharge 
assessing the association between PH and prolonged 
hospitalization. Among patients surviving to hospital 
discharge, PH was also significantly associated with 
prolonged LOS (OR, 1.14; 95% CI, 1.07– 1.21). There 
were also no significant interactions with either sex or 
age. These results are similar to those yielded by our 
main analyses, and it is thus unlikely that bias was intro-
duced in the main analyses due to in- hospital deaths.
DISCUSSION
To the best of our knowledge, this is the first analysis 
of in- hospital outcomes of patients with PH who had 
AIS, as well as the first to describe sex differences in 
AIS outcomes among patients with PH. We have found 
that 76.7% of patients with AIS with comorbid PH had 
concomitant left heart disease, chronic lung disease, 
or both, patients in whom PH is likely secondary to 
their cardiologic or respiratory comorbidities. Only 155 
(0.49%) patients with AIS were recorded to have PAH. 
Furthermore, we have found that upon multivariable 
adjustment for a wide range of confounders, includ-
ing heart and lung diseases, there was no association 
between PH and in- hospital mortality. Our analysis also 
revealed a significant sex interaction: compared with 
female patients with PH, male patients were 31% more 
likely to die in hospital, while PH was associated with a 
nonsignificant 15% increase in the odds of in- hospital 
mortality among male patients. Patients with AIS and 
PH were at increased odds for prolonged hospitaliza-
tion and less likely to be discharged routinely regard-
less of sex compared with patients with AIS without 
PH. Finally, our results suggest that patients with PH 
who were likely to have received prestroke treatment 
with anticoagulant agents had 23% decreased odds of 
in- hospital mortality and 12% decreased odds of pro-
longed hospitalization.
PH is a well- known risk factor for all- cause mortal-
ity37 and is also associated with incident cardiovas-
cular disease.10,38 A meta- analysis including 32  523 
patients, of whom 2976 (9.2%) had PH and a mean 
age of 52.2 years, found that patients with PH were at 
46% increased odds of incident stroke compared with 
those without PH.10 The findings of our study thus offer 
further insight into this otherwise poorly studied area. 
While PH was not overall associated with in- hospital 
mortality, our analyses showed an important sex differ-
ence: among patients with PH and AIS, male patients 
were 31% more likely to die in the hospital than female 
patients. Sex differences are well documented among 
patients with PH, with most data originating from stud-
ies on PAH.9 While female patients are generally more 
likely to develop PH, male patients with PH tend to have 
worse right ventricular function39 and generally worse 
outcomes than female patients with PH.9 The shorter 
life expectancy of male patients with PH compared 
with their female counterparts is also reflected in our 
included sample, given the increase in the proportion 
of female patients with PH with increasing age. The 
complete lack of an association between PH and AIS 
mortality is surprising, given that even mild elevations 
All (Pulmonary Hypertension) Male Female P Value
Disposition of the patient at discharge
Routine discharge 6495 (20.41) 2875 (25.56) 3620 (17.59) <0.001†
Transfer to short- term hospital 690 (2.17) 260 (2.31) 430 (2.09)
Transfer to other facility: includes skilled 
nursing facility, intermediate care facility, 
another type of facility
17 160 (53.91) 5450 (48.44) 11 710 (56.90)
Home health care 5240 (16.46) 1765 (15.69) 3475 (16.89)
Against medical advice 170 (0.53) 90 (0.80) 80 (0.39)
Died 2075 (6.52) 810 (7.20) 1265 (6.15)
Discharged alive, destination unknown <11* <11* <11*
IQR indicates interquartile range.
*Cell sizes ≤10 were not reported to avoid patient reidentification, according to the Healthcare Cost and Utilization Project guidelines.21
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in mean pulmonary artery pressure are associated with 
adverse mortality outcomes.37 Furthermore, patients 
with PH are more likely to develop right ventricular 
failure14 and decreased cardiac functional reserve15 
and may thus be more susceptible to the hemody-
namic instability and cardiac complications associated 
Figure 3. Results of multivariable logistic regressions assessing the association between pulmonary hypertension and in- 
hospital outcomes after acute ischemic stroke, including stratified analyses by sex and age groups.
*Overall regression results were derived from regression models not containing any interaction terms. All models were adjusted for age, 
sex, ethnicity, Elixhauser comorbidities and other comorbidities (dyslipidemia, smoking, coronary heart disease, all- cause bleeding, 
deep venous thrombosis/pulmonary embolism, pericarditis, infectious endocarditis, atrial fibrillation, pneumonia [including aspiration], 
chronic lung disease, shock, family history of cerebrovascular disease, family history of heart disease, previous cerebrovascular 
disease), hospital characteristics (location and teaching status), and endovascular treatment (thrombolysis and thrombectomy). LOS 
indicates length of stay; OR, odds ratio; P int, statistical significance level of interaction between grouping variable and pulmonary 
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with acute stroke.16,17 Our results showed that while 
more patients with PH died in the hospital compared 
with those without (6.52% versus 3.86%), there was 
no overall association upon comorbidity adjustment, 
including heart and lung disease. Given that 76.7% of 
patients with PH included in this study had coexisting 
cardiac and respiratory comorbidities and that these 
conditions are recognized independent risk factors for 
acute AIS mortality,37,40– 42 it is likely that the increased 
in- hospital mortality rates recorded among patients 
with PH may be mainly driven by these underlying con-
ditions and not by PH itself. Nevertheless, our results 
suggest that PH may be an independent risk factor for 
prolonged hospitalization and discharge disability re-
gardless of sex, highlighting that both male and female 
patients may still have an overall worse prognosis after 
AIS. Our analyses also highlight that age is an import-
ant factor to consider in the relationship between PH 
and AIS, given that PH was associated with decreased 
odds of routine discharge among patients >70 years 
old but not among those <70 years old. These differ-
ences may be driven by differences in ischemic stroke 
etiology and severity between younger and older pa-
tients with PH. Nevertheless, this cannot be confirmed 
in the absence of stroke type and severity (National 
Institutes of Health Stroke Scale) information.
This study benefited from several strengths. Having 
included a large patient sample representative of over 
1 million patients admitted between late 2015 and 2017 
across the United States, our results reflect contem-
porary stroke clinical practice and are generalizable 
to patients with similar demographic characteristics, 
such as those in North America, Western Europe, and 
Australia. Furthermore, we were able to adjust for a 
wide range of important confounders, including car-
diac and respiratory comorbidities as well as endovas-
cular therapies for AIS.
We acknowledge some limitations. Having con-
ducted our analyses on administrative data on the 
basis of ICD- 10 codes, we lacked information regard-
ing the severity of PH as well as the World Health 
Organization classification of PH. While we used 
ICD- 10 groups to establish the likely etiology of PH, 
the exact ascertainment of such PH causes was not 
possible without further clinical details. We were thus 
unable to perform stratified analyses by PH severity 
Table 3. Results of Multivariable Logistic Regressions 
Assessing the Association Between Pulmonary 
Hypertension and In- Hospital Outcomes After Acute 
Ischemic Stroke, Including Interaction Terms With Sex and 















































All models were adjusted for age, sex, ethnicity, Elixhauser comorbidities 
and other comorbidities (dyslipidemia, smoking, coronary heart disease, all- 
cause bleeding, deep venous thrombosis/pulmonary embolism, pericarditis, 
infectious endocarditis, atrial fibrillation, pneumonia [including aspiration], 
chronic lung disease, shock, family history of cerebrovascular disease, 
family history of heart disease, previous cerebrovascular disease), hospital 
characteristics (location and teaching status), and endovascular treatment 
(thrombolysis and thrombectomy). Statistically significant results (P<0.05) 
are displayed in bold.
AF indicates atrial fibrillation; ASVD, atherosclerotic vascular disease; 
LOS, length of stay; OR, odds ratio; and Ref, reference category.
*Overall regression results were derived from regression models not 
containing any interaction terms.
†Preexisting ASVD was defined as a composite of coronary heart disease, 
peripheral vascular disease, or previous stroke/transient ischemic attack.
‡Statistically significant result (P <0.05).
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or cause. Furthermore, we also lacked information re-
garding stroke severity, such as the National Institutes 
of Health Stroke Scale as well as stroke etiological 
classification. Furthermore, we lacked medication 
data. Nevertheless, we used preexisting dyslipidemia/
atherosclerotic vascular disease and AF as proxies for 
lipid- lowering therapy and anticoagulation, respec-
tively. Given that we analyzed a contemporary patient 
cohort, admitted between 2015 and 2017, it is reason-
able to assume that current cardiovascular preven-
tion recommendations were followed.35,36 Finally, it is 
important to note that statistically significant results 
may be commonly encountered in analyses of large 
samples and thus may not be necessarily be clinically 
relevant. Nevertheless, our analyses were prespecified 
and hypothesis- driven, with the relationship between 
comorbid PH and adverse AIS outcomes also being 
plausibly supported by the pathophysiological consid-
erations outlined above. It is thus likely that our results 
reflect these pathophysiological mechanisms in which 
the altered hemodynamic status associated with co-
morbid PH renders these patients more susceptible to 
adverse outcomes in the acute phase after AIS, rather 
than merely representing spurious statistically signifi-
cant associations.
Despite these limitations, our study has several 
important implications for further research and clin-
ical practice. The results of our study together with 
previous research10 suggest that PH is an important 
comorbidity to consider in the management of pa-
tients with AIS, given that patients with PH are not 
only at higher risk of AIS but also more likely to suffer 
worse acute outcomes after AIS. Patients with AIS 
and PH, especially male patients, may thus bene-
fit from therapeutic strategies personalized to their 
comorbidity profile, which may mitigate the PH- 
associated excess odds of adverse outcomes. While 
the evidence- based disease- modifying therapies 
used in PAH may not be used for the same purposes 
in patients with secondary PH, which comprise the 
majority of patients with PH included in our study, 
certain other simpler interventions may be consid-
ered and evaluated in further studies. These may 
include early cardiovascular and chest physician as-
sessment in the early stages after AIS. Furthermore, 
our results highlight for the first time that particular 
focus should be given to stroke prevention and man-
agement in older patients with PH, given that these 
patients are less likely to be discharged routinely 
compared with their younger counterparts. Our anal-
yses also suggest that preventative therapies such 
as antithrombotic therapy may improve outcomes 
in patients with PH and AIS. However, these results 
need to be confirmed in other registries with available 
medication and stroke severity data as well as ran-
domized clinical trials assessing optimal prevention 
strategies aiming to reduce the AIS burden in patients 
with PH. Our analyses also showed that patients with 
PH had a significantly higher prevalence of AF than 
those without PH: 56.83% versus 24.58%, respec-
tively. Given our results and previous evidence of the 
association between comorbid PH and increased 
risk of incident AIS,10 it is likely that the associations 
between PH and AIS may be at least partly mediated 
by AF. Systematic AF screening may thus be advo-
cated in patients with PH in line with current interna-
tional guidelines,43 since the timely identification and 
appropriate management of AF in patients with PH 
may improve AIS- related outcomes.
The results of our study also have several implications 
for further studies. Further research is required to deter-
mine the relationship between PH and postdischarge 
AIS outcomes, such as medium- and long- term mortality 
and stroke recurrence. Further case- control studies are 
also required to determine the relationship between more 
rare PH etiologies such as PAH and chronic thromboem-
bolic PH and AIS outcomes, given that we were unable 
to determine these relationships because of a low num-
ber of patients with PAH and chronic thromboembolic 
PH included in our study, consistent with the prevalence 
of these conditions in the general population.2,44
In conclusion, we reported for the first time the rela-
tionship between PH and AIS in- hospital outcomes, in 
a large, unselected, and representative sample. While 
PH was not overall associated with in- hospital mortal-
ity, it was associated with increased odds of prolonged 
hospitalization and adverse discharge status after AIS. 
There were also significant sex differences among pa-
tients with PH and AIS, in which male patients were 
more likely to die in hospital than female patients. 
Further studies assessing postdischarge outcomes in 
the medium and long term after AIS are required to fully 
characterize the relationship between PH and AIS.
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Table S1. International Classification of Disease – tenth edition (ICD-10) codes used to 
extract admission diagnoses, co-morbidities and procedures. 
Exposures ICD-10 codes (Diagnosis) 
Ischaemic Stroke I63.x 
Pulmonary Hypertension I27.x 
Patent Foramen Ovale/ 
Atrial Septal Defect 
Q21.1 
Co-morbidities  
Chronic Lung Disease J43.x – J47.x; J60.x – J67.x; J68.4; J68.8; J68.9; J84.0x; 
J84.111 – J84.113; J84.115 – J84.17; J84x  
Coronary Heart Disease I20.x – I25.x 
Deep Venous Thrombosis I82.x 
Pulmonary Embolism I26.x 
Pericarditis I30.x – I32 
Infectious Endocarditis I33.0; I33.9 
Atrial Fibrillation/Flutter I48.x 
Pneumonia J12.x – J18.x 
All-cause bleeding D69.8; D69.9; G97.x; H11.3x; H31.3x; H35.6x; H43.1x; 
H92.2x; I31.2; I60.x—I62.x; I85.01; I85.11; K25.x-
K29.x; K31.811; K62.5; K92.0-K92.2 I97.418; I97.42; 
I97.618-I97.621; J60.x-J62.x; N93.8; N93.9; N95.0; 





Family History of Stroke Z82.3 





Procedures ICD-10 codes (Procedural) 
Thrombolysis 03CG3ZZ; 03CG4ZZ; 03CK3Z7; 03CK3ZZ; 03CK4ZZ; 
03CL3Z7; 03CL3ZZ; 03CL4ZZ; 03CP3Z7; 03CP3ZZ; 
03CP4ZZ; 03CQ3Z7; 03CQ3ZZ; 03CQ4ZZ 
Thrombectomy 03CG3ZZ; 03CG4ZZ; 03CK3Z7 
Echocardiography B24; B244YZZ; B244ZZ3; B244ZZ4; B244ZZZ; 
B245YZZ; B245ZZ3; B245ZZ4; B245ZZZ; B246YZZ; 
B246ZZ3; B246ZZ4; B246ZZZ; B24BYZZ; B24BZZ3; 
B24BZZ4; B24BZZZ; B24CYZZ; B24CZZ3; B24CZZ4; 
B24CZZZ; B24DYZZ; B24DZZ3; B24DZZ4; B24DZZZ 
 








Table S2. International Classification of Disease – tenth edition (ICD-10) codes used to 




ICD-10 codes (Diagnosis) 
Pulmonary Arterial 
Hypertension 
Group 1 I27.0 
PH due to LHD Group 2 I27.2; I27.89; I27.9  
AND 
Q20.x-Q25.x; Q26.2-Q26.4;  
I42.x; I43; I50.x; I11.0; I13.0; I13.2; 
I34.x; I35.x I36.x; I37.x; I38; I39 
PH due to LHD & 
CLD 
Groups 2 and 3 I27.2; I27.89; I27.9  
AND 
Q20.x-Q25.x; Q26.2-Q26.4;  
I42.x; I43; I50.x; I11.0; I13.0; I13.2; 
I34.x; I35.x I36.x; I37.x; I38; I39; 
J43.x-J47.x; J60.x-J67.x; J68.4; J68.8; 
AND 
J68.9; J84.0x; J84.111- J84.113; J84.115-
J84.17; J84x 
PH due to CLD Group 3 I27.2; I27.89; I27.9  
AND 
J43.x-J47.x; J60.x-J67.x; J68.4; J68.8; 
J68.9; J84.0x; J84.111- J84.113; J84.115-
J84.17; J84x 
CTEPH Group 4 I27.82 
Other causes Group 5 I27.2; I27.89; I27.9  
AND 
Not classified in any of the above 
categories 
 
PH – Pulmonary Hypertension; LHD – left heart disease; CLD – chronic lung disease; 








Table S3. Patient characteristics on admission, stratified by co-morbid pulmonary hypertension and age group (≤40; 41-50; 51-60 
years). Also see Supplementary Table 6 for age groups 61-70; 71-80 and >80 years. 
 ≤ 40 years 41-50 years 51-60 years 
 No PH PH P value No PH PH P value No PH PH P value 
N 29520 370  68230 860  172905 2385  







































Female, N (%) 
14715 
(49.85) 
190 (51.35) 0.798 
30150 
(44.19) 







MORBIDITIES, N (%) 
         
Congestive Heart 
Failure 






Valvular Disease 1840 (6.23) 110 (29.73) <0.001 3495 (5.12) 295 (34.30) <0.001 9085 (5.25) 710 (29.77) <0.001 
Pulmonary Circulation 
Disease 





30 (8.11) 0.380 5685 (8.33) 75 (8.72) 0.854 
14665 
(8.48) 
345 (14.47) <0.001 
Paralysis 4270 
(14.46) 
95 (25.68) 0.009 
8920 
(13.07) 
175 (20.35) 0.005 
19390 
(11.21) 
355 (14.88) 0.012 
Other Neurological 
Disorders 
290 (0.98) 20 (5.41) <0.001 590 (0.86) 25 (2.91) 0.005 1210 (0.70) 50 (2.10) <0.001 
Chronic Pulmonary 
Disease 
2825 (9.57) 60 (16.22) 0.054 
7515 
(11.01) 
215 (25.00) <0.001 
25325 
(14.65) 
770 (32.29) <0.001 
Diabetes (without 
chronic complications) 
2235 (7.57) 15 (4.05) 0.253 
10345 
(15.16) 
140 (16.28) 0.681 
31805 
(18.39) 
400 (16.77) 0.361 




70 (18.92) 0.062 
14615 
(21.42) 
215 (25.00) 0.265 
42065 
(24.33) 









1465 (4.96) 15 (4.05) 0.721 4385 (6.43) 40 (4.65) 0.340 
12480 
(7.22) 
210 (8.81) 0.187 
Renal Failure 
1705 (5.78) 70 (18.92) <0.001 6325 (9.27) 150 (17.44) <0.001 
19630 
(11.35) 
725 (30.40) <0.001 
Liver Disease 445 (1.51) 20 (5.41) 0.007 1275 (1.87) 25 (2.91) 0.316 4560 (2.64) 110 (4.61) 0.007 
Peptic Ulcer Disease 95 (0.32) <11 0.626 330 (0.48) <11 0.207 950 (0.55) 15 (0.63) 0.816 
Acquired Immune 
Deficiency Syndrome 
190 (0.64) <11 0.497 435 (0.64) <11 0.926 970 (0.56) 15 (0.63) 0.878 
Lymphoma 40 (0.14) <11 0.008 130 (0.19) <11 0.566 530 (0.31) <11 0.658 
Metastatic Cancer 145 (0.49) <11 0.540 625 (0.92) <11 0.735 2690 (1.56) 65 (2.73) 0.039 
Solid tumour without 
metastasis 
125 (0.42) <11 0.566 425 (0.62) <11 0.315 2010 (1.16) 25 (1.05) 0.816 
Rheumatoid Arthritis / 
Collagen Vascular 
Disease 
960 (3.25) 45 (12.16) <0.001 1540 (2.26) 15 (1.74) 0.652 3530 (2.04) 120 (5.03) <0.001 
Coagulopathy 1165 (3.95) 20 (5.41) 0.520 1940 (2.84) 75 (8.72) <0.001 5390 (3.12) 140 (5.87) <0.001 
Obesity 6490 
(21.99) 
110 (29.73) 0.123 
16495 
(24.18) 
290 (33.72) 0.005 
33500 
(19.37) 
645 (27.04) <0.001 
Weight loss 635 (2.15) 20 (5.41) 0.057 1365 (2.00) 45 (5.23) 0.003 4580 (2.65) 145 (6.08) <0.001 




100 (27.03) 0.026 
13280 
(19.46) 
285 (33.14) <0.001 
35050 
(20.27) 
740 (31.03) <0.001 
Anaemia (chronic 
blood loss) 
130 (0.44) <11 0.246 385 (0.56) <11 0.329 370 (0.21) 20 (0.84) .004 
Anaemia (deficiency) 3020 
(10.23) 
95 (25.68) <0.001 
7480 
(10.96) 
190 (22.09) <0.001 
15250 
(8.82) 
450 (18.87) <0.001 
Alcohol abuse 
1605 (5.44) 30 (8.11) 0.317 4920 (7.21) 60 (6.98) 0.905 
15880 
(9.18) 
180 (7.55) 0.207 
Drug abuse 2990 
(10.13) 
35 (9.46) 0.850 5480 (8.03) 70 (8.14) 0.959 
11580 
(6.70) 
210 (8.81) 0.062 
Psychoses 1340 (4.54) <11 0.189 3185 (4.67) 50 (5.81) 0.475 6950 (4.02) 110 (4.61) 0.510 
Depression  3095 
(10.48) 
35 (9.46) 0.776 
8495 
(12.45) 
105 (12.21) 0.924 
21280 
(12.31) 










215 (58.11) 0.063 
51140 
(74.95) 







MORBIDITIES, N (%) 
         




80 (21.62) 0.176 
33560 
(49.19) 










85 (22.97) 0.164 
24790 
(36.33) 
250 (29.07) 0.045 
63870 
(36.94) 
705 (29.56) 0.001 
Parkinson Disease 15 (0.05) <11 0.846 70 (0.10) <11 
.69500000
00000001 
390 (0.23) <11 0.379 
Transient Ischaemic 
Attack 
165 (0.56) <11 0.355 410 (0.60) <11 0.973 1195 (0.69) <11 0.473 
Rheumatic Heart 
Disease 
435 (1.47) 55 (14.86) <0.001 875 (1.28) 175 (20.35) <0.001 2420 (1.40) 385 (16.14) <0.001 
Coronary Heart 
Disease 
2240 (7.59) 90 (24.32) <0.001 
10290 
(15.08) 






All-cause Bleeding 1995 (6.76) 50 (13.51) 0.023 3910 (5.73) 105 (12.21) <0.001 
10225 
(5.91) 
285 (11.95) <0.001 





80 (21.62) 0.017 3880 (5.69) 75 (8.72) 0.089 6675 (3.86) 135 (5.66) 0.043 
Pericarditis <11 <11 0.911 <11 <11 - 25 (0.01) <11 0.792 
Infectious Endocarditis 245 (0.83) <11 0.082 270 (0.40) 15 (1.74) 0.006 430 (0.25) 15 (0.63) 0.103 
Atrial Fibrillation 1115 (3.78) 55 (14.86) <0.001 3940 (5.77) 185 (21.51) <0.001 
15685 
(9.07) 
615 (25.79) <0.001 
Deep Venous 
Thrombosis 
465 (1.58) 35 (9.46) <0.001 1125 (1.65) 50 (5.81) <0.001 2690 (1.56) 70 (2.94) 0.016 
Pneumonia 580 (1.96) 25 (6.76) 0.004 1375 (2.02) 50 (5.81) <0.001 3850 (2.23) 155 (6.50) <0.001 
Chronic Lung Disease 500 (1.69) <11 0.508 3510 (5.14) 130 (15.12) <0.001 
18575 
(10.74) 










415 (1.41) <11 0.299 3260 (4.78) 115 (13.37) <0.001 
17600 
(10.18) 
615 (25.79) <0.001 
Shock 140 (0.47) 20 (5.41) <0.001 260 (0.38) 25 (2.91) <0.001 795 (0.46) 55 (2.31) <0.001 
Family history of 
cerebrovascular disease 
2140 (7.25) 15 (4.05) 0.292 4435 (6.50) 25 (2.91) 0.056 9040 (5.23) 120 (5.03) 0.848 
Family history of heart 
disease 
2280 (7.72) 35 (9.46) 0.579 5635 (8.26) 65 (7.56) 0.756 
12930 
(7.48) 





20 (5.41) 0.180 
8760 
(12.84) 
70 (8.14) 0.063 
23295 
(13.47) 
325 (13.63) 0.921 
PROCEDURES, N (%)          
Thrombectomy 1500 (5.08) 50 (13.51) 0.001 2410 (3.53) 50 (5.81) 0.109 5270 (3.05) 140 (5.87) <0.001 
Thrombolysis 3570 
(12.09) 
65 (17.57) 0.177 
8180 
(11.99) 
85 (9.88) 0.397 
17015 
(9.84) 
260 (10.90) 0.448 
Echocardiography 5835 
(19.77) 
110 (29.73) 0.032 
10385 
(15.22) 
150 (17.44) 0.410 
20225 
(11.70) 
370 (15.51) 0.010 
OUTCOMES, N (%)          
In-hospital mortality 695 (2.35) 35 (9.46) <0.001 1365 (2.00) 35 (4.07) 0.056 3920 (2.27) 105 (4.40) 0.003 
Length-of-stay >4 days 10235 
(34.67) 
230 (62.16) <0.001 
21855 
(32.03) 






Routine Discharge 19040 
(66.07) 
170 (46.58) <0.001 
39500 
(59.54) 
395 (46.20) <0.001 
89545 
(52.87) 




         
Year of admission   0.351   0.112   <0.001 
  2015 2985 
(10.11) 
30 (8.11)  6780 (9.94) 85 (9.88)  
17220 
(9.96) 
260 (10.90)  
  2016 13050 
(44.21) 
140 (37.84)  
30390 
(44.54) 






  2017 13485 
(45.68) 
200 (54.05)  
31060 
(45.52) 
325 (37.79)  
79780 
(46.14) 
880 (36.90)  










105 (28.38)  
34555 
(50.64) 








150 (40.54)  
18790 
(27.54) 
295 (34.30)  
43790 
(25.33) 
790 (33.12)  
Hispanic 3820 
(12.94) 
65 (17.57)  
7780 
(11.40) 
90 (10.47)  
16035 
(9.27) 
210 (8.81)  
Asian or Pacific 
Islander 
860 (2.91) 15 (4.05)  2155 (3.16) 55 (6.40)  4620 (2.67) 50 (2.10)  
Native American 190 (0.64) <11  405 (0.59) <11  1010 (0.58) 30 (1.26)  
Other 1175 (3.98) <11  1965 (2.88) 25 (2.91)  4845 (2.80) 55 (2.31)  










Table S4. Patient characteristics on admission, stratified by co-morbid pulmonary hypertension and age group (61-70; 71-80; >80 years) 
(continued). Also see Supplementary Table 5 for age groups ≤40; 41-50; 51-60 years. 
 61-70 years 71-80 years >80 years 
 No PH PH P value No PH PH P value No PH PH P value 
N 249585 4950  256060 7990  297915 15275  
























































MORBIDITIES, N (%) 























































































































































Liver Disease 5770 (2.31) 200 (4.04) <0.001 3520 (1.37) 200 (2.50) <0.001 1975 (0.66) 210 (1.37) <0.001 
Peptic Ulcer Disease 1705 (0.68) 65 (1.31) 0.018 1910 (0.75) 80 (1.00) 0.244 2380 (0.80) 155 (1.01) 0.196 
Acquired Immune 
Deficiency Syndrome 
520 (0.21) 35 (0.71) <0.001 185 (0.07) <11 0.887 35 (0.01) <11 0.549 
Lymphoma 1080 (0.43) 40 (0.81) 0.077 1660 (0.65) 55 (0.69) 0.843 1655 (0.56) 110 (0.72) 0.238 
Metastatic Cancer 5370 (2.15) 115 (2.32) 0.723 5170 (2.02) 190 (2.38) 0.311 3405 (1.14) 170 (1.11) 0.881 
Solid tumour without 
metastasis 
4410 (1.77) 150 (3.03) 0.003 5915 (2.31) 205 (2.57) 0.502 6080 (2.04) 325 (2.13) 0.735 
Rheumatoid Arthritis / 
Collagen Vascular 
Disease 
6185 (2.48) 210 (4.24) <0.001 8040 (3.14) 425 (5.32) <0.001 8500 (2.85) 580 (3.80) 0.002 
Coagulopathy 
8660 (3.47) 405 (8.18) <0.001 
10215 
(3.99) 
575 (7.20) <0.001 
11930 
(4.00) 













990 (6.48) <0.001 
Weight loss 
8555 (3.43) 375 (7.58) <0.001 
10230 
(4.00) 
480 (6.01) <0.001 
16355 
(5.49) 
1245 (8.15) <0.001 



















710 (0.28) 35 (0.71) 0.013 915 (0.36) 55 (0.69) 0.031 1265 (0.42) 135 (0.88) <0.001 















Alcohol abuse 15610 
(6.25) 
315 (6.36) 0.886 7610 (2.97) 235 (2.94) 0.943 2790 (0.94) 140 (0.92) 0.917 
Drug abuse 6435 (2.58) 185 (3.74) 0.022 1440 (0.56) 60 (0.75) 0.318 460 (0.15) 40 (0.26) 0.126 
Psychoses 6755 (2.71) 155 (3.13) 0.415 4420 (1.73) 95 (1.19) 0.100 3095 (1.04) 95 (0.62) 0.026 
Depression  30335 
(12.15) 
750 (15.15) 0.005 
28205 
(11.01) 





























MORBIDITIES, N (%) 
         




















245 (4.95) 0.205 
31160 
(12.17) 









895 (18.08) <0.001 
30490 
(11.91) 
815 (10.20) 0.038 9825 (3.30) 450 (2.95) 0.279 
Parkinson Disease 2065 (0.83) 20 (0.40) 0.144 5420 (2.12) 145 (1.81) 0.407 7380 (2.48) 280 (1.83) 0.023 
Transient Ischaemic 
Attack 
1830 (0.73) 40 (0.81) 0.785 2020 (0.79) 40 (0.50) 0.196 2255 (0.76) 95 (0.62) 0.399 
Rheumatic Heart 
Disease 





























585 (11.82) <0.001 
19600 
(7.65) 
960 (12.02) <0.001 
24155 
(8.11) 
1470 (9.62) 0.002 
Pulmonary Embolism 1695 (0.68) 95 (1.92) <0.001 1435 (0.56) 155 (1.94) <0.001 1360 (0.46) 200 (1.31) <0.001 
Congenital Heart 
Disease 
7615 (3.05) 185 (3.74) 0.210 6205 (2.42) 245 (3.07) 0.105 4390 (1.47) 385 (2.52) <0.001 
Pericarditis 25 (0.01) <11 0.009 25 (0.01) <11 <0.001 <11 <11 0.749 



















3590 (1.44) 180 (3.64) <0.001 3270 (1.28) 220 (2.75) <0.001 2885 (0.97) 265 (1.73) <0.001 
Pneumonia 5875 (2.35) 325 (6.57) <0.001 6980 (2.73) 375 (4.69) <0.001 9545 (3.20) 770 (5.04) <0.001 








































Shock 1225 (0.49) 90 (1.82) <0.001 1200 (0.47) 90 (1.13) <0.001 1075 (0.36) 95 (0.62) 0.020 




150 (3.03) 0.074 8525 (3.33) 265 (3.32) 0.978 7235 (2.43) 390 (2.55) 0.666 




275 (5.56) 0.334 
13740 
(5.37) 
495 (6.20) 0.143 
11870 
(3.98) 
















PROCEDURES, N (%)          
Thrombectomy 7535 (3.02) 280 (5.66) <0.001 7865 (3.07) 430 (5.38) <0.001 8195 (2.75) 695 (4.55) <0.001 
Thrombolysis 22670 
(9.08) 
490 (9.90) 0.371 
23070 
(9.01) 








490 (9.90) 0.641 
22940 
(8.96) 
800 (10.01) 0.150 
17095 
(5.74) 
1145 (7.50) <0.001 
OUTCOMES, N (%)          
In-hospital mortality 
7110 (2.85) 295 (5.96) <0.001 9740 (3.80) 465 (5.82) <0.001 
18640 
(6.26) 
1140 (7.46) 0.007 

































         
Year of admission   0.195   <0.001   <0.001 
  2015 24280 
(9.73) 
535 (10.81)  
26350 
(10.29) 












































































300 (6.06)  
18090 
(7.06) 
440 (5.51)  
17545 
(5.89) 
620 (4.06)  
Asian or Pacific 
Islander 
7250 (2.90) 125 (2.53)  7545 (2.95) 150 (1.88)  8395 (2.82) 415 (2.72)  
Native American 1285 (0.51) 25 (0.51)  985 (0.38) 25 (0.31)  715 (0.24) 30 (0.20)  
Other 6600 (2.64) 115 (2.32)  6200 (2.42) 140 (1.75)  6020 (2.02) 310 (2.03)  
Missing 
8575 (3.44) 185 (3.74)  8680 (3.39) 300 (3.75)  
10185 
(3.42) 










 Figure S1. Results of sensitivity multivariable logistic regressions assessing the 
association between pulmonary hypertension and prolonged hospitalisation after acute 
ischaemic stroke only including patients surviving to hospital discharge. 
 
*Overall regression results were derived from regression models not containing any interaction 
terms 
Models were adjusted for age, sex, ethnicity, Elixhauser co-morbidities and other co-
morbidities (dyslipidaemia, smoking, coronary heart disease, all-cause bleeding, deep venous 
thrombosis/pulmonary embolism, pericarditis, infectious endocarditis, atrial fibrillation, 
pneumonia (incl. aspiration), chronic lung disease, shock, family history of cerebrovascular 
disease, family history of heart disease, previous cerebrovascular disease), hospital 
characteristics (location and teaching status) and endovascular treatment (thrombolysis and 
thrombectomy). 
OR – odds ratio; CI – confidence interval; P int – Statistical significance level of interaction 
between grouping variable and pulmonary hypertension; Ref – Reference category; LoS – 
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